S&P 500   3,324.80 (+0.24%)
DOW   29,322.11 (+0.08%)
QQQ   222.83 (+0.25%)
AAPL   316.76 (+0.48%)
FB   221.91 (+0.06%)
GOOGL   1,465.98 (+1.09%)
AMZN   1,864.29 (-0.73%)
CGC   25.03 (+3.00%)
NVDA   248.12 (-0.33%)
MU   57.64 (-0.07%)
GE   11.82 (-0.17%)
AMD   50.94 (+2.35%)
T   38.33 (+0.79%)
ACB   2.09 (-2.80%)
F   9.16 (-0.22%)
BAC   34.61 (-0.32%)
GILD   62.96 (-0.40%)
DIS   144.73 (-0.27%)
S&P 500   3,324.80 (+0.24%)
DOW   29,322.11 (+0.08%)
QQQ   222.83 (+0.25%)
AAPL   316.76 (+0.48%)
FB   221.91 (+0.06%)
GOOGL   1,465.98 (+1.09%)
AMZN   1,864.29 (-0.73%)
CGC   25.03 (+3.00%)
NVDA   248.12 (-0.33%)
MU   57.64 (-0.07%)
GE   11.82 (-0.17%)
AMD   50.94 (+2.35%)
T   38.33 (+0.79%)
ACB   2.09 (-2.80%)
F   9.16 (-0.22%)
BAC   34.61 (-0.32%)
GILD   62.96 (-0.40%)
DIS   144.73 (-0.27%)
S&P 500   3,324.80 (+0.24%)
DOW   29,322.11 (+0.08%)
QQQ   222.83 (+0.25%)
AAPL   316.76 (+0.48%)
FB   221.91 (+0.06%)
GOOGL   1,465.98 (+1.09%)
AMZN   1,864.29 (-0.73%)
CGC   25.03 (+3.00%)
NVDA   248.12 (-0.33%)
MU   57.64 (-0.07%)
GE   11.82 (-0.17%)
AMD   50.94 (+2.35%)
T   38.33 (+0.79%)
ACB   2.09 (-2.80%)
F   9.16 (-0.22%)
BAC   34.61 (-0.32%)
GILD   62.96 (-0.40%)
DIS   144.73 (-0.27%)
S&P 500   3,324.80 (+0.24%)
DOW   29,322.11 (+0.08%)
QQQ   222.83 (+0.25%)
AAPL   316.76 (+0.48%)
FB   221.91 (+0.06%)
GOOGL   1,465.98 (+1.09%)
AMZN   1,864.29 (-0.73%)
CGC   25.03 (+3.00%)
NVDA   248.12 (-0.33%)
MU   57.64 (-0.07%)
GE   11.82 (-0.17%)
AMD   50.94 (+2.35%)
T   38.33 (+0.79%)
ACB   2.09 (-2.80%)
F   9.16 (-0.22%)
BAC   34.61 (-0.32%)
GILD   62.96 (-0.40%)
DIS   144.73 (-0.27%)
Log in

NASDAQ:CFRX - ContraFect Stock Price, Forecast & News

$1.04
-0.07 (-6.28 %)
(As of 01/17/2020 02:02 PM ET)
Today's Range
$1.01
Now: $1.05
$1.08
50-Day Range
$0.29
MA: $0.58
$1.23
52-Week Range
$0.27
Now: $1.05
$1.34
Volume1.65 million shs
Average Volume3.65 million shs
Market Capitalization$160.22 million
P/E RatioN/A
Dividend YieldN/A
Beta0.51
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CFRX
CUSIPN/A
Phone914-207-2300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.07 per share

Profitability

Net Income$-37,680,000.00

Miscellaneous

Employees20
Market Cap$160.22 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive CFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter.


Forget 5G - here's the next big thing (Ad)


Investing in 5G is old news. I discovered a company with a revolutionary new technology that could be the next Cisco. I expect their $5 stock to climb to $90 and eventually as high as $1,200 per share. A $1,000 investment could grow to as much as $240,000.

ContraFect (NASDAQ:CFRX) Frequently Asked Questions

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

How were ContraFect's earnings last quarter?

ContraFect Corp (NASDAQ:CFRX) issued its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.01. View ContraFect's Earnings History.

When is ContraFect's next earnings date?

ContraFect is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for ContraFect.

What price target have analysts set for CFRX?

2 brokerages have issued twelve-month target prices for ContraFect's stock. Their forecasts range from $1.50 to $2.00. On average, they expect ContraFect's stock price to reach $1.75 in the next twelve months. This suggests a possible upside of 68.3% from the stock's current price. View Analyst Price Targets for ContraFect.

What is the consensus analysts' recommendation for ContraFect?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraFect.

Has ContraFect been receiving favorable news coverage?

News stories about CFRX stock have been trending very negative on Friday, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ContraFect earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for ContraFect.

Are investors shorting ContraFect?

ContraFect saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 341,900 shares, an increase of 338.3% from the November 28th total of 78,000 shares. Based on an average daily volume of 714,900 shares, the short-interest ratio is presently 0.5 days. Currently, 0.5% of the company's shares are short sold. View ContraFect's Current Options Chain.

Who are some of ContraFect's key competitors?

What other stocks do shareholders of ContraFect own?

Who are ContraFect's key executives?

ContraFect's management team includes the folowing people:
  • Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 66)
  • Mr. Michael Messinger CPA, CPA, CFO & Chief Accounting Officer (Age 44)
  • Ms. Nancy Dong, VP of Fin. & Admin. (Age 54)
  • Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 50)
  • Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 57)

How do I buy shares of ContraFect?

Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ContraFect's stock price today?

One share of CFRX stock can currently be purchased for approximately $1.04.

How big of a company is ContraFect?

ContraFect has a market capitalization of $159.45 million. The biotechnology company earns $-37,680,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. ContraFect employs 20 workers across the globe.View Additional Information About ContraFect.

What is ContraFect's official website?

The official website for ContraFect is http://www.contrafect.com/.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]


MarketBeat Community Rating for ContraFect (NASDAQ CFRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  380
MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe CFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel